Story perspectives

Arrowhead's Obesity Drug Shows Promise, Stock Surges 17%

1/6/2026

Summary

Story summary

Arrowhead Pharmaceuticals disclosed early-phase results for its gene-silencing drug candidate ARO-INHBE in obesity.
In a Phase 1/2 study, patients receiving ARO-INHBE with Eli Lilly's Zepbound lost 9.4% of body weight over 16 weeks, versus 4.8% for those on Zepbound alone.
The study also reported significant reductions in visceral fat and liver fat.
The data do not establish ARO-INHBE's effectiveness as a standalone treatment.
Arrowhead's stock rose about 17% amid investor interest and rising competition in the obesity-treatment market.

1 of 1

Story summary

Arrowhead Pharmaceuticals disclosed early-phase results for its gene-silencing drug candidate ARO-INHBE in obesity.
In a Phase 1/2 study, patients receiving ARO-INHBE with Eli Lilly's Zepbound lost 9.4% of body weight over 16 weeks, versus 4.8% for those on Zepbound alone.
The study also reported significant reductions in visceral fat and liver fat.
The data do not establish ARO-INHBE's effectiveness as a standalone treatment.
Arrowhead's stock rose about 17% amid investor interest and rising competition in the obesity-treatment market.